北大医药股份有限公司关于获得《药品补充申请批准通知书》的公告

Core Viewpoint - North Medical Pharmaceutical Co., Ltd. has received approval for a supplemental application for Olanzapine Tablets, enhancing its product portfolio in the field of mental health [1][2]. Group 1: Drug Information - The drug Olanzapine is an antipsychotic used for treating schizophrenia and can effectively maintain clinical symptom improvement in patients responding to initial treatment [2]. - It is also indicated for the treatment of moderate to severe manic episodes and can prevent the recurrence of bipolar disorder in patients who respond to treatment [2]. Group 2: Impact on the Company - The approval of Olanzapine Tablets will improve the company's product structure in the mental health sector, enhancing its competitiveness in the market and positively impacting future performance [3]. Group 3: Shareholder Information - North Medical, a major shareholder, has recently completed the process of releasing part of its pledged shares, indicating a potential strengthening of shareholder confidence [6]. - The company will continue to monitor developments related to this matter and fulfill its disclosure obligations as required by law [6].